Efficacy and safety of Flutiform pMDI in adult patients with mild to moderate-severe reversible asthma

Trial Profile

Efficacy and safety of Flutiform pMDI in adult patients with mild to moderate-severe reversible asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Formoterol/fluticasone propionate; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Mundipharma International
  • Most Recent Events

    • 22 Sep 2010 Primary endpoint 'Forced expiratory volume in 1 second' has been met.
    • 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society
    • 22 Jul 2008 Primary endpoint met, according to a SkyePharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top